SAN DIEGO, Feb. 07, 2017 -- Square 1 Bank, a division of Pacific Western Bank, today announced that it has provided a $4 million credit facility to new client Recursion Pharmaceuticals, Inc., a leading pharmaceutical discovery company. Proceeds from the facility will be used to purchase new equipment and supplement Recursion’s recent $15.05 million Series A round of funding.
Based in Salt Lake City, Recursion Pharmaceuticals employs an innovative platform that leverages advanced biological science, computation and artificial intelligence to efficiently discover treatments for rare genetic disease and other conditions which can be modeled in human cells. In 2016, the company received national recognition for its commitments towards President Obama’s Precision Medicine Initiative, a national effort to develop patient-specific treatments which take differences between individuals into account.
“Square 1 has been a great banking partner in every sense of the word; professional, experienced and willing to develop a tailored solution to meet our needs,” noted John Pereira, chief operating officer at Recursion. “They understand how early stage companies operate and the fast pace at which we work and innovate. I’m excited to have their support as we grow.”
“In three short years, Recursion’s strong management team and innovative platform have established the company as a true leader in its field,” added Rilus Graham, senior vice president in Square 1’s life sciences practice. “Square 1 is excited to continue to grow our presence in Salt Lake City through our support of Recursion and its mission to treat 100 diseases in 10 years.”
About Square 1 Bank
Square 1 Bank is a division of Pacific Western Bank, a Los Angeles-based commercial bank with over $21 billion in assets. A full service financial services partner to entrepreneurs and their investors, Square 1 provides clients flexible resources and attentive service to help their companies grow. Square 1 offers a broad range of venture debt, treasury and cash management solutions through offices in top innovation centers: Atlanta, Austin, the Bay Area, Boston, Chicago, Denver, Durham, Los Angeles, Minneapolis, New York, San Diego, Seattle and Washington, DC. Pacific Western Bank is a wholly-owned subsidiary of PacWest Bancorp (NASDAQ:PACW). For more information, visit www.square1bank.com.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a Salt Lake City-based drug discovery company. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Learn more at www.recursionpharma.com, or connect on Twitter (@RecursionPharma), Facebook (www.facebook.com/RecursionPharma/), and LinkedIn (https://www.linkedin.com/company/recursion-pharmaceuticals)
Media Contact: Square 1 Bank, a division of Pacific Western Bank Dee McDougal 919.597.7479 [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



